LifeStance Health appoints new chief technology officer

SCOTTSDALE, Ariz. - LifeStance Health (NASDAQ:LFST), a major provider of outpatient mental health services generating annual revenues of $1.28 billion with a market capitalization of $2.28 billion, announced the appointment of Vaughn Paunovich as its new Chief Technology Officer, set to take his position on June 9, 2025. Paunovich’s role will involve spearheading the company’s comprehensive technology strategy and enhancing the technological experience for both patients and healthcare providers.

With over two decades of experience in healthcare technology, Paunovich’s previous tenure includes significant roles at Amwell and UnitedHealth Group, where he was instrumental in leading digital transformation efforts. His expertise is expected to further LifeStance’s mission by improving access to mental health services and fostering the development of patient-centered technologies. According to InvestingPro data, the company has demonstrated strong growth with revenue increasing by 16.3% in the last twelve months.

Dave Bourdon, CEO of LifeStance, expressed confidence in Paunovich’s ability to execute the company’s long-term technology vision and maintain the quality of patient and clinician experiences. Paunovich himself is eager to contribute to LifeStance’s ongoing efforts to revolutionize mental health care delivery in the United States.

Paunovich will be succeeding Pablo Pantaleoni, who has been credited with pivotal contributions to LifeStance’s digital transformation since 2020. A smooth transition is anticipated, with Pantaleoni working closely with Paunovich.

LifeStance, founded in 2017 and publicly traded as NASDAQ:LFST, operates in 33 states with over 550 centers, employing roughly 7,500 mental health professionals. The company’s approach to mental health care focuses on providing accessible, affordable, and personalized services to children, adolescents, and adults facing various mental health conditions. InvestingPro analysis indicates the company maintains a healthy financial position with a current ratio of 1.47 and analysts expect profitability this year. Get detailed insights and access to more than 10 additional ProTips with an InvestingPro subscription.

This announcement is based on a press release statement from LifeStance Health. For comprehensive analysis including Fair Value estimates, financial health scores, and expert insights, access the full Pro Research Report available exclusively on InvestingPro.

In other recent news, LifeStance Health Group Inc. reported its Q1 2025 earnings, marking a significant milestone with its first positive net income of $700,000. The company achieved an 11% year-over-year revenue growth, reaching $333 million, and adjusted EBITDA increased by 25%, amounting to $35 million. Despite revenue coming in slightly below expectations at $332.97 million compared to the forecast of $333.33 million, the earnings per share (EPS) of $0 surpassed the forecasted EPS of -$0.0215. LifeStance Health has set a full-year revenue guidance of $1.4 billion to $1.44 billion, anticipating growth driven by increased visit volumes. Additionally, the company plans to open 25-30 new centers, suggesting a strategic expansion. Analysts have shown interest in the company’s disciplined approach to mergers and acquisitions, as well as its focus on organic growth. The recent developments reflect LifeStance Health’s ongoing improvements and operational efficiencies, positioning it for continued growth in the mental health services sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.